Using the OHD4–12, we demonstrate that it interrupts the CXCL12-driven migration of breast cancer cells, thus establishing the role of CXCL4–CXCL12 heterodimer in breast cancer and suggesting its utility for therapeutic advantage. Here, CXCL12 is linked to breast carcinoma.